|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 21 - Issue 1, January-February 2019
PHARMACEUTICAL CARE IN PATIENTS WITH MIGRAINE
FERNÁNDEZ PAREDES PATRICIA, BENEDÍ GONZALEZ JUANA, IGLESIAS PEINADO IRENE
Introduction: Migraine is one of the most frequent pathologies of the central nervous system and affects one in 10 people in the world, is more frequent in women (two out of three), and usually occurs between 20 and 50 years of age. It is a very disabling disease that presents with a headache that varies in intensity, frequency
and location and may be accompanied or not by aura.
1) To analyze the use of anti-migraine drugs in adults from the participating pharmacies in the study.
2) To decrease the frequency and intensity of migraine attacks as well as emergency healthcare related to this disease through pharmaceutical care.
Method: A longitudinal, prospective, single-blind study was designed, based on the data retrieved from the participating pharmacies where patients included in the study received pharmaceutical advice. The protocol, defined to obtain all the relevant data, was based on different life quality tests and was further completed
with detailed questionnaires.
Results: Most respondents are young and middle-aged women (80%), active and of Spanish nationality. The most used drugs are triptans (49.41%) and antiinflammatory (29.41%). Stress is the most common trigger in our population (18.82%). The patients of the experimental group, who received active pharmaceutical care, suffered a greater decrease in the degree of disability (52.27%) compared to the control group (12.2%). Among the experimental group, 68.18% noticed an improvement in the degree of intensity of the crises compared to 39.02% in the control group. And 52.27% of the experimental group claimed to suffer seizures less frequently than at the beginning of the follow-up, compared to 31.71% of the control group.
Conclusion: Migraine is one of the most disabling diseases. The non-pharmacological resources used such as oral and written communication on recommendations for the correct use of drugs, food and healthy lifestyles have been useful to improve the quality of life since patients acquire the tools to be able to know
the triggers of their migraine attacks.
HEADACHE – MIGRAINE – PHARMACEUTICAL CARE